# **SUPPLEMENTARY TABLE 4** Univariate analysis examining association between baseline clinico-pathological factors and PSA response in patients switched onto enzalutamide after collection of circulating cell-free DNA (*n* = 39)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variable** | ***n*** | **PSA50 %** | ***P*** | **PSA30 %** | ***P*** |
| AR copy number increase ± AR exon 8 mutation in cfDNA  Yes  No | 19  20 | 21  50 | 0.06 | 21  60 | **0.013** |
| AR copy number increase in cfDNA  Yes  No | 14  25 | 21  44 | 0.16 | 21  52 | 0.06 |
| Prior docetaxel  Yes  No | 18  21 | 33  38 | 0.76 | 33  48 | 0.37 |
| Gleason score  ≤ 7  8-10 | 13  23 | 31  35 | 1.00 | 31  43 | 0.45 |
| ECOG performance status  0-1  ≥ 2 | 28  11 | 43  18 | 0.27 | 50  18 | 0.09 |
| Visceral metastases  Absent  Present | 33  6 | 39  17 | 0.40 | 45  17 | 0.37 |
| Serum LDH (IU/L)  > 250  ≤ 250 | 18  21 | 24  38 | 0.39 | 33  48 | 0.37 |
| Serum ALP (IU/L)  > 160  ≤ 160 | 19  20 | 21  45 | 0.16 | 21  55 | 0.07 |
| Circulating tumor cells  ≥ 5  < 5 | 18  18 | 22  50 | 0.08 | 28  56 | 0.09 |
| No. lines systemic treatment^  ≥ 3  ≤ 2 | 25  14 | 36  36 | 0.51 | 44  36 | 0.61 |
| DNA concentration (ng/µL) (continuous) | 39 | NA | 0.23 | NA | 0.14 |
| Hemoglobin (continuous) | 39 | NA | 0.22 | NA | 0.22 |

Association between variables and PSA response was examined using either Χ2 for categorical variables or logistic regression for continuous variables.

PSA50: PSA decline ≥ 50% maintained for ≥ 3 weeks

PSA30: PSA decline ≥ 30% maintained for ≥ 3 weeks

AR: Androgen receptor

ECOG: Eastern Co-operative group

LDH: Lactate dehydrogenase

ALP: Alkaline phosphatase

Circulating tumor cells: per 7.5 ml blood

^: Number of lines of systemic treatment beyond initial androgen deprivation therapy (LHRH agonist/antagonist)